SynthesisEuropean journal of nuclear medicine and molecular imaging2026
The [
Synthesis in European journal of nuclear medicine and molecular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
purposeThis study aims to perform a systematic review and meta-analysis of prognostic significance of pretreatment [18F]FDG PET/CT parameters in patients with multiple myeloma (MM).
methodsA systematic literature search was performed in PubMed, Web of Science, Embase, and Cochrane Library databases from database inception until March 15, 2025. The risk of bias was assessed using Quality In Prognosis Studies (QUIPS). The hazard ratios (HRs) of [18F]FDG PET/CT parameters were meta-analytically pooled using random-effects model, with progression free survival (PFS) and overall survival (OS) serving as end points.
resultsA total of 54 studies were included, among which over 10 [18F]FDG PET/CT parameters were reported. For PFS, the pooled HRs of presence of extramedullary disease (EMD), presence of paramedullary disease (PMD), higher SUV, higher total metabolic tumor volume (TMTV), higher total lesion glycolysis (TLG), and larger number of focal lesions (FLs) were 2.80 (95% CI: 2.05–3.83), 2.57 (95% CI: 1.39–4.76), 2.06 (95% CI: 1.71–2.48), 3.25 (95% CI: 1.10–9.57), 4.30 (95% CI: 1.07–17.31), and 1.66 (95% CI: 1.32–2.09). For OS, the corresponding HRs were 3.52 (95% CI: 2.49–4.99), 1.43 (95% CI: 0.82–2.49), 2.35 (95% CI: 1.72–3.22), 3.11 (95% CI: 0.83–11.66), 3.82 (95% CI: 1.23–11.86), and 1.66 (95% CI: 1.24–2.21), respectively.
conclusionsThe presence of EMD, higher SUV, and larger number of FLs were significantly associated with shorter PFS and OS, and could serve as prognostic predictors in MM. The presence of PMD, higher TMTV and TLG exhibited the potential prognostic value for risk stratification in MM.
Indexed as
Identifiers
41792563What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.